Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison by Fraser, Hannah et al.
                          Fraser, H., Vellozzi, C., Hoerger, T., Evans, J., Kral, A. H., Havens, J.,
Young, A., Stone, J., Handanagic, S., Hariri, S., Barbosa, C.,
Hickman, M., Leib, A., Martin, N., Nerlander, L., Raymond, H., Page,
K., Zibbell, J., Ward, J., & Vickerman, P. (2019). Scaling-up Hepatitis
C Prevention and Treatment Interventions for Achieving Elimination in
the United States – a Rural and Urban Comparison. American Journal
of Epidemiology, 188(8), 1539–1551. [kwz097].
https://doi.org/10.1093/aje/kwz097
Peer reviewed version
Link to published version (if available):
10.1093/aje/kwz097
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Oxford University Press at https://academic.oup.com/aje/article/188/8/1539/5509380. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving 
Elimination in the United States – a Rural and Urban Comparison 
 
Hannah Fraser, Claudia Vellozzi, Thomas J. Hoerger, Jennifer L. Evans, Alex H. Kral, 
Jennifer Havens, April M. Young, Jack Stone, Senad Handanagic, Susan Hariri, Carolina 
Barbosa, Matthew Hickman, Alyssa Leib, Natasha K. Martin, Lina Nerlander, Henry F. 
Raymond, Kimberly Page, Jon Zibbell, John W. Ward and Peter Vickerman.  
 
Correspondence to Dr Hannah Fraser, Population Health Sciences, Bristol Medical School, 
University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK (e-mail: 
hannah.fraser@bristol.ac.uk; phone number: +44 (0) 117 3310140) 
 
Author affiliations: Population Health Sciences, Bristol Medical School, University of 
Bristol, Bristol, UK (Hannah Fraser, Jack Stone, Matthew Hickman, Natasha Martin and 
Peter Vickerman); Division of Medical Affairs, Grady Health System, Atlanta, Georgia, USA 
(Claudia Vellozzi); RTI International, Research Triangle Park, USA (Thomas J Hoerger, 
Alex H Kral, Carolina Barbosa, Jon Zibbell); Institute for Global Health Sciences, University 
of California San Francisco, San Francisco, USA (Jennifer L. Evans);  Center on Drug and 
Alcohol Research, Department of Behavioral Science, University of Kentucky College of 
Medicine, Kentucky, USA (Jennifer Havens, April M. Young); Department of Epidemiology, 
University of Kentucky College of Public Health, Kentucky, USA (April M. Young); 
Division of HIV/AIDS Prevention (DHAP), U.S. Centers for Disease Control and Prevention, 
Atlanta, USA (Senad Handanagic, Lina Nerlander); Division of Viral Hepatitis, US Centers 
for Disease Control and Prevention, Atlanta, USA (Susan Hariri and John W. Ward); 
Department of Chemistry, University of Colorado, Denver, USA (Alyssa Leib); Division of 
Infectious Diseases and Global Public Health, Department of Medicine, University of 
California San Diego, San Diego, USA (Natasha K. Martin); Center for Public Health 
Research, Population Health Division, San Francisco Department of Public Health, 25 Van 
Ness Ave. San Francisco CA, USA 94102 (Henry F. Raymond); Department of Internal 
Medicine, School of Medicine, University of New Mexico Health Sciences Center, USA 
(Kimberly Page); Coalition for Global Hepatitis Elimination, Task Force for Global Health, 




This study was supported by Contract No. 200-2013-M-53964B GS-10F-0097L from 
the Centers for Disease Control and Prevention (CDC) to RTI International and a subcontract 
from RTI International to the University of Bristol. The opinions expressed in this paper are 
solely those of the authors and do not necessarily represent the opinions of the CDC, RTI 
International, or the University of Bristol. 
 NKM, PV, and MH were additionally supported by the National Institute for Drug 
Abuse [grant number R01 DA037773], and NM was partially funded by the University of 
California San Diego Center for AIDS Research(CFAR), a National Institute of Health (NIH) 
funded program [grant number P30 AI036214]. PV and MH acknowledge support from the 
National Institute of Health Research Health Protection Research Unit in Evaluation of 




DA016017-14) as was JH (R01 DA024598). JS acknowledges funding from a PhD 
scholarship from the Engineering and Physical Sciences Research Council (EPSRC)  
 
Conflict of Interest: 
 NKM and PV have received unrestricted research grants from Gilead unrelated to this 
work, and NKM has received honoraria from Merck, AbbVie, and Janssen.  MH has received 
honoraria unrelated to this work from Merck, Abbvie and Gilead. HF has received an 
honorarium from MSD. JS has received a conference attendance sponsorship from Gilead. 
KP has received research grant funding from Gilead unrelated to this work. JW, SH, AY, CV, 
AK, JZ and TH declare no conflict of interest.  
 




Word count:  3,657 
 
Abbreviations 
DAA - direct-acting antivirals 
HCV – Hepatitis C virus 
HR – harm reduction 
MAT - medication-assisted treatment 
NHBS - National HIV Behavioural Surveillance  
PWID – people who inject drugs 
SNAP - Social Networks Among Appalachian People 
SSP - syringe service programs  
UHS – Urban Health Study 






Abstract: (200 words) 
In the U.S. Hepatitis C virus (HCV) transmission is increasing among people who inject 
drugs (PWID). Many regions have insufficient prevention intervention coverage. Using 
modelling, we investigate the impact of scaling-up prevention and treatment interventions on 
HCV transmission among PWID in Perry County, Kentucky (PC), and San Francisco, 
California (SF), where HCV sero-prevalence among PWID is >50%. A greater proportion of 
PWID access medication-assisted treatment (MAT) or syringe service programs (SSP) in 
urban SF (established community) than rural PC (young, expanding community). We model 
the proportion of HCV-infected PWID needing HCV-treatment annually to reduce HCV-
incidence by 90% by 2030, with and without MAT scale-up (50% coverage, both settings) 
and SSP scale-up (PC only) from 2017. With current MAT&SSP coverage during 2017-2030, 
HCV-incidence will increase in PC (21.3 to 22.6 per 100 person-years (/100pyrs)) and 
decrease in SF (12.9 to 11.9/100pyrs). With concurrent MAT&SSP scale-up, 5%/year of 
HCV-infected PWID need HCV-treatment in PC to achieve incidence targets; 13%/year 
without MAT&SSP scale-up. In SF, a similar proportion need HCV-treatment (10%/year) 
irrespective of MAT scale-up. Reaching the same impact by 2025 requires increases in 
treatment rates of 45-82%. Achievable provision of HCV-treatment, alongside MAT&SSP 
scale-up (PC) and MAT scale-up (SF), could reduce HCV-incidence.  
 
Keywords: direct-acting-antiviral HCV-treatment; Hepatitis C virus; medication-assisted 






An estimated 3.5 million individuals are infected with hepatitis C virus (HCV) in the United 
States (U.S)1, with annual mortality rates greater than for HIV2. In the U.S., over 80% of 
HCV transmission occurs among people who inject drugs (PWID)3.  
 
Harm reduction (HR) services for PWID such as medication-assisted treatment (MAT) and 
syringe service programs (SSPs) can reduce the risk of HCV acquisition4,5. All-oral direct-
acting antivirals (DAA) cure HCV in 8-12 weeks6,7. Modelling from non-U.S. settings8-13 has 
shown scaling-up HR alongside DAAs could substantially reduce the HCV-burden. This is 
crucial for achieving the World Health Organization (WHO) and U.S. National Academies of 
Sciences, Engineering and Medicine (NASEM)14 HCV elimination targets of reducing HCV 
incidence by 90% by 203014-16.    
 
The availability of HR services17-19 varies across the U.S., with some cities having established 
SSPs20,21 whilst other settings having none17,18,22. PWID demographics and their associated 
HCV transmission patterns23,24 also vary geographically. Most large cities have established 
PWID populations25 and stable HCV infection rates, while rural settings have an expanding 
younger demographic of PWID22 with increasing HCV transmission24. This expansion is 
particularly acute in Appalachia, where the prevalence of injecting and rate of new HCV 
infections have increased 3-fold between 2006-201224,26.  
 
In this study, we model the epidemic situation among PWID in San Francisco (California) 
and Perry County (Kentucky), capturing differences in HR availability, HCV epidemiology, 
and injecting drug use dynamics. In line with WHO and the U.S. National Academies of 




scale-up of HR interventions and HCV-treatment to decrease HCV incidence in these settings 






We developed two deterministic HCV transmission models among PWID (see Web Figures 
1-4); one for each setting. The models differed in several ways due to differences in data 
availability.  
 
The modelled PWID population in both sites was stratified by risk status (high-risk defined as 
sharing works (syringes/cottons/cookers) in past 6 months), intervention status (on MAT 
and/or SSP or neither) and HCV infection status. PWID demographics differed between the 
sites; with the Perry County model stratifying by injecting duration (<3 and ≥3 years) and the 
San Francisco model stratifying by age (15-24, 25-29, 30-49 and 50+ years). Both models 
incorporated time-varying rates of initiating injecting, with PWID leaving due to injecting 
cessation (unaffected by MAT status) or mortality (drug or non-drug related). Injecting 
cessation is via temporary cessation in the San Francisco model (if relapse does not occur), 
but not in the Perry County model due to insufficient data. Due to the long timeframe 
associated with HCV disease progression and mortality27 we assumed no additional mortality 
due to HCV complications or the impact of HIV co-infection on this, with the former 





In both settings, individuals initiate injecting as low- or high-risk, HCV susceptible without 
HR. PWID transition between risk and intervention states over time. HCV transmission 
occurs at a per-capita rate, dependent on chronic HCV-infection prevalence (RNA-positive), 
with transmission risk reduced if PWID are on HR interventions5, but increased if they are 
high-risk or young/new. Mixing between PWID to form transmission contacts ranges from 
random to fully like-with-like, either by age or duration of injecting and risk status.  
 
Once infected, some individuals spontaneously clear infection30,31, moving to the previously 
infected group, while the remainder develop chronic HCV-infection. Chronic HCV-infection 
is lifelong unless treated, which typically results in cure (sustained viral response, SVR). We 
assume all PWID have equal access to treatment irrespective of disease stage because we are 
modelling to maximise prevention benefits. Cured individuals are susceptible to re-infection 
at the same level as for primary infection, independent on age, injecting risk and intervention 
status.  Those not cured remain chronically HCV-infected but can be retreated.  
 
Web Appendices 1 and 2 give further model details. 
 
Model parameterisation and calibration  
Most model parameters for Perry County and San Francisco are context-specific. Exceptions 
were the efficacy of MAT and SSP, assumed to individually reduce transmission risk by 50% 
and 56%, respectively5, with efficacies multiplied if PWID access both. Both models 
assumed no HCV-treatment at baseline because local experts suggest treatment for active 
PWID was negligible before DAAs become available. Model parameters are given in Tables 
1-3, with most parameters having uncertainty distributions assigned to them (usually 95% 




sets for each setting, with this variability being propagated to the model projections. For 
each sampled parameter set, unknown model parameters (see below) were estimated through 
model calibration to data using a non-linear least squares algorithm in MATLAB, giving a 
large number of baseline model fits for each setting. This model calibration was checked to 
ensure it accurately fit the data.  
 
Perry County, Kentucky 
The Perry County model was parameterised primarily using data from the Social Networks 
Among Appalachian People (SNAP) study, analysed for this project (Table 2)22. This on-
going longitudinal study of PWID from Perry County started in 2008, initially recruiting 
through respondent driven sampling. See Web Appendix 1 for details. 
 
[Table 2 here] 
 
The time-varying number of individuals initiating injecting annually and their cessation rate 
were calibrated to give the estimated PWID population size for Perry County in 2009 (700+/-
20%, analysis for this project), while assuming an 8-fold increase in the number of 
individuals initiating injecting over 1990-2000 (Web Figure 5); consistent with other data26.  
 
Based on SNAP data, we assumed 14.5% of PWID were high-risk (reported sharing works in 
last 6 months), with an increased HCV acquisition risk (3.2-fold). Movement of PWID from 
low- to high-risk was estimated through model calibration while assuming the rate that PWID 
transition from high to low-risk is 0.47 per year.  SNAP data suggested MAT coverage was 
4.7% in 2009, but there was no SSP. The recruitment rate onto MAT was derived through 




MAT of 6 months based on SNAP data. We assumed PWID injecting <3 years had greater 
HCV acquisition risk (2.2-fold) compared to those injecting ≥3years. Because SNAP data22 
suggests 87.3% of PWID injecting ≥3 years have an injection partner that has injected ≥3 
years, we assumed this same like-with-like mixing in the model. We assume PWID inject for 
5-25 years.  
 
The baseline HCV transmission rate (among low-risk PWID not accessing HR and injecting 
≥3years) was estimated through model calibration to the HCV sero-prevalence among those 
injecting <3 years in 2009 (36.0%). SNAP data on HCV sero-prevalence in those injecting ≥3 
years in 2009 and HCV incidence over 2008-2015 (PWID injecting < 3 years or ≥3 years) 
were used for model validation.  
 
San Francisco, California 
The San Francisco model was parameterised with data from the UFO Study 32,33 (young adult 
PWID <30 years enrolled in prospective follow-up since 2000), the National HIV 
Behavioural Surveillance (NHBS) System for PWID 17,18,21,34, and the Urban Health Study 
(UHS)35 (Table 3). See Web Appendix 2 for details.  
 
[Table 3 here] 
 
The age individuals start injecting came from UHS and NHBS data17,34, while the temporary 
cessation rate (cessation incidence 16%/100 pyrs) for PWID <30 years and injecting relapse 
rates (incidence of relapse 56/100 pyrs for those aged 15-29 and 30/100pyrs for those aged ≥
30) came from UFO data36. The temporary cessation rate of PWID aged ≥30, permanent 




estimated through calibrating the model  to the estimated number of PWID aged <30 years 
(~6,000) and ≥30 years (~20,000) in San Francisco for 200725, and the proportion aged ≥3034. 
 
Time-varying recruitment rates on to MAT and SSP were estimated through calibrating a 
sub-model to the changing coverage of MAT and SSP, while assuming a duration on 
MAT/SSP of 1.0 year37. Based on UFO data we assumed MAT started in 2000, increased to 
2.6% coverage by 2004 and 12.2% by 2015. SSP started in 198920, and was assumed to scale-
up to high coverage (83.7% obtained needles from a SSP in last month) by 199720, and then 
remain stable17,18. 
 
Based on UFO data, we assumed 61.1% of PWID were high-risk (reported sharing works in 
last 6 months) pre-2002 and 48.3% post-2002, with an increased HCV acquisition risk (1.6-
fold – UFO data analysis). Movement of PWID from low- to high-risk pre-2002 and post-
2002 was estimated through model calibration whilst assuming the rate PWID transition from 
high- to low-risk is 1.6 annually (UFO data), i.e. over 100% generally transition from high- to 
low-risk in a year.  
 
We estimated baseline model transmission rates (among low-risk PWID not accessing HR) 
for PWID aged <30 and ≥30 years by calibrating the model to HCV incidence in PWID <30 
years for 2000-2001 (25.1 per 100pyrs)32,38 and HCV sero-prevalence among PWID aged 
≥50 years (96.3%) in 199935. Estimates of HCV sero-prevalence in other age-groups were 
used for model validation. Lastly, because UFO data suggests 58.0% of PWID aged <30 
years have an injection partner aged <30 years, we assumed this same like-with-like mixing 









The baseline model fits for each setting were used to estimate the impact on chronic HCV 
prevalence and incidence of scaling-up MAT to 50% coverage and SSP coverage in Perry 
County to the same as San Francisco (84%) (denoted full harm reduction, full HR), with or 
without treating 20 or 50 per 1000 (/1000) PWID at any stage of disease progression with 
DAAs annually, all from 2017 onwards. For each baseline model fit, we then determined the 
annual HCV-treatment rate required among PWID to decrease HCV incidence by 90% by 
2025 or 2030, with or without full HR.  
 
Uncertainty analysis 
To ascertain which parameters are important for determining variability in the projections 
across the baseline model fits, a linear regression analysis of covariance (ANCOVA)39 was 
performed on the projected initial percentage of chronically HCV-infected PWID needing 
HCV-treatment each year to reduce incidence by 90% by 2030 with full HR. The proportion 
of the sum of squares contributed by each parameter was calculated to determine each 









For Perry County, 5,000 baseline model fits were obtained (see Figure 1, Web Appendix 3 
and Web Figures 6 and 7), with 90% of these fits lying within the 95% confidence intervals 
(95%CI) of one of the validation data points (see methods) and 33.6% lying within two or 
more.  
 
For Perry County, the model projected that chronic HCV prevalence and incidence fell from 
1990 due to increasing susceptible PWID entering the population. Chronic HCV prevalence 
then increased post-2000 as the PWID population began to stabilise (Figure 1). HCV chronic 
prevalence is estimated to be 59.5% in 2017, and without intervention scale-up, is projected 
to increase to 65.0% by 2030. Similarly, from 2017-2030, HCV incidence will increase from 
21.3 to 22.6 per 100pyrs (/100pyrs). Conversely, with full HR scale-up from 2017, HCV 
chronic prevalence and incidence will decrease by 35.3% (95% credibility interval (95%CrI) 
12.7-71.5%) and 77.0% (95%CrI 47.6-92.2%) by 2030, respectively. Additionally, treating 
20/1,000 or 50/1,000 PWID annually with DAAs (equivalent to 3.4% or 8.3% of chronic 
HCV-infections being treated in the first-year, Web Table 1) would decrease incidence to 
low-levels, by 86.0% (95%CrI 60.1-99.4%) or 99.2% (95%CrI 79.7-100.0%) over 2017-
2030, respectively.  
 
[Figure 1 here] 
For San Francisco, 997 baseline model fits were obtained (see Figure 2, Web Appendix 3 and 
Web Figures 8 and 9), with 89.4% of these model fits lying within the 95%CI of one of the 
validation data points (see methods) and 37.1% lying within two.  
 
For San Francisco, the model projects that HCV incidence decreased considerably after 1989 




HCV incidence has stabilised at 12.9/100pyrs and chronic HCV prevalence is projected to be 
75.5% (Figure 2). Without intervention scale-up, both are projected to remain stable until 
2030. Conversely, scaling-up to full HR will decrease chronic HCV prevalence by 10.7% 
(95%CrI 7.0-15.8%) and incidence by 30.4% (95%CrI 22.7-37.4%) by 2030. Additionally, 
treating 20/1,000 or 50/1,000 PWID (equivalent to 2.7% or 6.6% of chronic HCV-infections 
being treated in the first-year, Web Table 2) would decrease incidence by 56.3% (95%CrI 
44.9-63.6%) or 86.9% (95%CrI 75.3-95.7%) by 2030, respectively.  
 
[Figure 2 here] 
 
Treatment scale-up for reaching HCV-elimination targets 
With or without full HR scale-up, a 90% reduction in incidence is possible in Perry County 
and San Francisco by 2030 if sufficient HCV-treatment occurs (Figure 3). In San Francisco, 
scaling-up to full HR has little impact due to existing moderate to high levels of coverage; 
with 8-9% of chronically HCV-infected PWID initially needing treatment each year (1,418-
1,574 treatments in first year, 56-63/1,000 PWID annually) to reduce incidence by 90% by 
2030. Conversely, in Perry County, scaling-up to full HR has more impact, with the resulting 
HCV-treatment rate being less than San Francisco (4.7% of chronically HCV-infected PWID 
initially needing treatment each year - 22 treatments in first year or 26.6/1000 PWID per 
year). However, the treatment is over two-fold greater than this (12.6% - 58 treatments or 
73.1/1000 PWID per year) without full HR scale-up. To achieve the same impact by 2025, 
the initial required treatment rates in both sites need to be increased by 45-60% without full 
HR or 60-82% with full HR (Figure 3), but the overall cumulative number of PWID needing 
treatment is similar (Web tables 3 and 4).  Table 4 presents all these results with 95% credible 




needing treatment to reach the elimination targets than the yearly percentage needing 
treatment. Similar treatment numbers are needed to achieve a 90% reduction in prevalence 
(Web Figure 10).  
 
[Figure 3 here] 
 
Uncertainty analysis 
For Perry County, uncertainty in the permanent cessation rate contributes to three-quarters of 
the variation (74%) in the projected yearly percentage of chronically HCV-infected PWID 
needing HCV-treatment to reach the incidence target (Web Figure 11a). Uncertainty in HCV 
sero-prevalence in 2009 and heightened transmission risk among recently initiated PWID 
also account for 15% and 6% of the variation, respectively. Conversely, for San Francisco, 
uncertainty in the HCV prevalence among PWID aged ≥ 50 in 1999 contributes a third 
(32%) to the variability in the yearly treatment percentage (Web Figure 11b). The level of 
like-with-like mixing by age, SVR rate, year when the rate of initiation of new injectors 
decreased, and HCV-incidence amongst PWID aged <30 in 2000-2001 contribute a further 
18%, 18%, 14% and 8%, respectively. In both settings, other parameters contribute <5% to 
the variation.  
 
DISCUSSION 
Aligned with the WHO’s HCV-elimination strategy, the U.S. National Academies of 
Sciences, Engineering and Medicine recently developed strategy for the U.S. sets targets to 
reduce HCV incidence by 90% by 2030.  For two U.S. settings, urban San Francisco and 
rural Perry County, our model projections suggest modest HCV-treatment uptake (<20% of 




concurrent MAT (to 50% of PWID) and SSP (only needed in Perry County, to 84% of 
PWID) scale-up, only 5-9% of chronically HCV-infected PWID need treating annually to 
decrease HCV incidence by 90% in both settings by 2030. Conversely, without scaling-up 
these interventions, higher HCV-treatment rates (13% annually) are needed in Perry County, 
but not San Francisco. To achieve the same impact by 2025, HCV-treatment rates need to 
increase by over half in both settings. Encouragingly, recent Australian data suggests these 
treatment rates are achievable (21% of infected PWID treated in 201640).  
 
With HR scale-up, achieving the HCV incidence elimination target by 2030 will initially 
require 1,418 annual HCV-treatments among PWID in San Francisco, but only 22 in Perry 
County (19,019 and 288 overall between 2017-2030). Although these treatment numbers for 
San Francisco are comparable to the 1,400 planned for 2017, and 2,100 for 2018 and 2019, 
by the San Francisco Department of Public Health “End Hep C SF” initiative41, these 
treatment targets are for all groups – illustrating additional treatment scale-up among PWID 
may be necessary. This will require expanding HCV case-finding and treatment 
interventions, likely involving MAT and SSP and prison interventions. The feasibility of such 
strategies is being evaluated in the U.S.42-44, and are planned by the End Hep C SF 
initiative41, and in Kentucky. However, their scale-up will be a challenge; HR interventions 
are limited in most U.S. settings, with about half of PWID not accessing SSP in the last 
year,17 and the nearest SSP being on average 37 miles away19. Nationwide expansion of HR 
interventions is necessary to enable scale-up of community-based testing and treatment 
interventions, requiring substantial additional resources to HCV case-finding and treatment 
costs. This expansion will have other benefits though45,46, and will reduce the number of 





Strengths and Limitations 
The strength of our modelling is undertaking detailed site-specific models. Unlike previous 
models evaluating the impact of HCV prevention and treatment interventions9,10,48, our 
models incorporate the changing epidemiology of each setting. We use empirical estimates 
for MAT and SSP efficacy5, and incorporate how HCV transmission risk differs by other 
factors, improving the validity of our projections.  
 
Despite this, our modelling is subject to limitations. First, the empirical estimates for efficacy 
of SSP5 are uncertain.  We used synthesised estimates for SSP from Europe instead of North 
America as review level evidence from North America suggests little protective benefit of 
SSP compared to a halving in risk from European studies5. Explanations for this difference 
include differences in measurement of exposure to high coverage SSP, greater confounding 
by indication in studies from North America (where high-risk PWID are more likely to use 
SSP49), and reduced benefit in stimulant injectors. We assumed European efficacy estimates 
on the basis that U.S. SSPs should achieve the same impact as in Europe if they are designed 
in a similar way. 
 
Second, empirical data availability and uncertainties contributed to uncertainty in our model 
projections. Specifically, although recent HCV incidence estimates were available for San 
Francisco38, HCV prevalence estimates were unavailable post-200035. While our model 
agrees with existing data, only further data collection will confirm whether our model fully 
captures the current HCV epidemic in San Francisco.  Additionally, limited data on PWID 
population size estimates25 meant it was difficult to determine changing PWID population 
dynamics over time. Improved size estimation studies are needed to better understand the 




particularly during the current opioid crisis. Importantly, even with current levels of data 
uncertainty, the model still projected important insights on required levels of prevention and 
treatment needed to eliminate HCV.  
 
Third, we did not model HIV co-infection. While HIV prevalence among PWID is negligible 
in Kentucky22, 12% of PWID were HIV-positive in San Francisco in 201221. This should not 
have affected our projections due to the low incidence of new infections (<1/100pyrs) in San 
Francisco50 and low HIV-related mortality51 because many HIV-infected PWID (66%) are on 
HIV treatment.21 Additionally, we did not explicitly model the consequences of HCV on 
mortality. This was done because it is unlikely to substantially contribute to mortality 
amongst current PWID as found in previous mortality studies from North America28,52.   
 
Fourth, we did not model men who have sex with men (MSM) that have heightened HCV 
risk and may overlap with PWID. This was done because recent data from the NHBS survey 
suggest that MSM that inject drugs probably have different injecting networks to non-MSM 
PWID due to differences in the primary drug injected and transmission among MSM 
frequently being linked to high-risk sexual activities, unlike in PWID53. This is supported by 
phylogenetic analyses from Europe suggesting a separate epidemic of HCV among MSM to 
PWID54.  
 
Lastly, we did not model the process through which HCV-treatment scale-up will be 
undertaken or financed, which needs to be considered in future analyses.  
 




Previous modelling for non-U.S. settings have estimated the impact of scaling-up HR 
services, with or without HCV-treatment scale-up8-11,13. Recent U.S. modelling studies have 
considered the impact of HCV-treatment among prisoners55, and PWID in urban48 and non-
urban settings47,56. These have generally not accounted for local heterogeneity, and/or used 
relatively simple models47,55. One study used a more complex network-based model, 
suggesting comparable treatment rates were needed in their lower prevalence scenario (60% 
chronic HCV prevalence) as projected for Perry County, but higher treatment rates were 
needed in their high prevalence scenario (75%) than we projected for San Francisco. The 
reasons why our model suggested lower treatment rates being needed in San Francisco are 
uncertain, but could be due to the reductions in HCV incidence that resulted from high SSP 
availability. Our modelling complements this and other analyses, by undertaking detailed 
site-specific modelling in two contrasting settings, using longitudinal data to capture changes 
in their HCV epidemics. This allowed us to consider whether the impact of scaling-up 
prevention and treatment interventions could vary across urban and non-urban locations in 
the U.S., typifying the main epidemic types occurring. Importantly, one crucial difference 
between our model and many previous models57,58 is that we assume a constant number being 
treated each year instead of a rate of treatment which decreases as chronic prevalence 
decreases. Previous modelling59 has shown the limitation of this latter assumption because it 
results in much higher treatment rates being initially needed to compensate for large 




Despite the existence of effective harm reduction (HR) interventions5, the availability of 




HCV-treatment as prevention strategies60.  Our modelling can guide these initiatives by 
projecting the HCV-treatment needed to eliminate HCV infection as a public health 
threat8,9,47. Our study reveals that modest scale-up of HCV-treatment, together with MAT and 
SSP where needed, can reverse the expanding HCV burden in the U.S, reaching elimination 
goals in 10-15 years. In urban areas (e.g. San Francisco) with existing moderate to high-
coverage of HR services, HCV-treatment should be scaled up to reduce transmission. 
Conversely, in U.S. settings with low-coverage of HR services19, scaling-up MAT and SSP is 
also necessary to reduce incidence of new and re-infections, enhancing the impact of HCV-
treatment as prevention strategies. Scaling-up MAT and SSP also enables the expansion of 
case-finding, necessary to increase HCV-treatment uptake among PWID61-64. Field studies 
are required to demonstrate the feasibility and impact of these strategies, helping inform HR 







Figure 1: The impact of different intervention scenarios on (a) chronic hepatitis C virus 
(HCV) prevalence among all people who inject drugs (PWID) and (b) incidence among 
susceptible PWID over time in Perry County, Kentucky. Median projections for each 
intervention scenario applied to the baseline model fits are shown with the 95% credibility 
intervals (95%CrI) only included for the no intervention scale-up scenario for the baseline 
model fits. Medication-assisted treatment (MAT) is assumed to start between 1990 and 1999 
and is scaled-up from 2017 to 50% coverage. Both syringe service programs (SSP) and HCV-
treatment are started in 2017, SSP scaling-up to 84% coverage and treatment to either 
20/1000 PWID or 50/1000 PWID respectively. The grey points show chronic HCV 
prevalence and incidence data from the SNAP study, which was not fit to, but is shown for 
comparison. Note that the model was fit to data on antibody prevalence among those 
injecting < 3yrs in 2009 (36.0% (22.9-50.8%)). Incidence is estimated among susceptible 
PWID. In both figures the pale grey area shows the 95%CrI for the no intervention scale-up 
scenario; the solid black line shows the median of model runs for the no intervention scale-up 
scenario; the pale grey solid line shows the median of model for scale-up to 84% SSP and 
50% MAT coverage (Full harm reduction (HR); the dashed mid-grey line shows the median 
of model runs for full HR and HCV-treating 20 per 1000 PWID annually; the dot-dashed 
dark-grey line shows the median of model runs for full HR and HCV-treating 50 per 1000 
PWID annually; the solid dark grey dot and vertical line shows the data estimate and it’s 95% 
confidence interval from the Social Networks Among Appalachian People study and the 









Figure 2: The impact of different intervention scenarios on chronic hepatitis C virus (HCV) 
prevalence (a) and incidence (b) among people who inject drugs (PWID) over time in San 
Francisco, California. Median projections for each intervention scenario applied to the 
baseline model fits are shown with the 95% credibility intervals only included for the no 
intervention scale-up scenario for the baseline model fits (no intervention scale-up). Syringe 
service programs (SSP) is assumed to start in 1989 and is stable at a high coverage (84%) 
from 1997. Medication-assisted treatment (MAT) is assumed to scale-up to 50% coverage 
from 2017 and HCV-treatment also starts in 2017 with either 20/1000 PWID or 50/1000 
PWID treated annually. The model was fit to data on HCV incidence in PWID <30 for 2000-
2001 (25.1/100pyrs; 95% CI 18.7-32.9)32,38 and HCV sero-prevalence among PWID aged 
≥50 years (96.3%; 95% CI 94.3-98.7%) in 199935. Incidence is estimated among susceptible 
PWID. No incidence data estimate shown for the whole PWID population because of a lack 
of data, whereas an estimated chronic HCV prevalence for the whole population is shown in 
Figure 2a, which was obtained from an available HCV sero-prevalence data estimate for 1999 
by adjusting it for the modelled proportion of antibody positive PWID that have chronic 
HCV-infection. In both figures the pale grey area shows the 95%CrI for the no intervention 
scale-up scenario; the solid black line shows the median of model runs for the no intervention 
scale-up scenario; the pale grey solid line shows the median of model for scale-up to 50% 
MAT coverage (alongside 84% SSP coverage - full harm reduction (HR); the dashed mid-
grey line shows the median of model runs for full HR and HCV-treating 20 per 1000 PWID 
annually; the dot-dashed dark grey line shows the median of model runs for full HR and 
HCV-treating 50 per 1000 PWID annually; the vertical dotted grey line in 1989 shows when 
SSP was scaled-up in San Francisco and the vertical dotted grey line in 2017 shows when we 
model scale-up of MAT and HCV-treatment from; the solid dark grey dot and vertical line in 











Figure 3: (a) Annual number needing treatment per 1000 people who inject drugs (PWID) 
and (b) initial percentage of chronic infections requiring treatment per year to decrease HCV 
incidence by 90% by 2025 or 2030 in Perry County and San Francisco. Figures show the 
projected number per 1000 PWID and initial percentage of chronic infections that need to be 
treated each year to decrease incidence by 90% by 2030 or 2025 in Perry County (Kentucky – 
solid bars) and San Francisco (California – striped bars), without and with full harm 
reduction (50% medication-assisted treatment (MAT) and 84% syringe service programs 
(SSP) coverage). In all figures, bars show the median projections across all baseline model 
fits for Perry County and San Francisco, and the whiskers show the 95% credibility intervals. 
The solid bars are for Perry County and striped bars are for San Francisco, with the dark grey 
showing the number/percentage needed without MAT/SSP scale-up and the light grey 
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Table 1: Shared natural history and intervention related parameters and uncertainty bounds for Perry County, Kentucky and San Francisco, 
California.  
Parameter Mean 95%CI Point estimate Range Distribution References 
 Prevention intervention effectiveness parameters 
Relative risk of acquiring HCV while on MATa 0.5  0.4, 0.63   Log-normal 5 
Relative risk of acquiring HCV while on SSPa 0.44 0.24, 0.80   Log-normal 5 
 HCV-Treatment and clearance parameters 
SVR rate (%)    85–95  Uniform 7 
Duration of treatment (weeks)   12   N/A 7 
Treatment start yearb   2017  N/A  
Average proportion of infections that clear spontaneously    0.22–0.29 Uniform 30 
Abbreviations: HCV: hepatitis C virus; MAT: medication-assisted treatment; SSP: syringe service programs; SVR: sustained viral response; 95%CI: 95% confidence 






Table 2: Model parameters and calibration data with uncertainty bounds (usually 95% confidence intervals) for Perry County, Kentucky.  
Parameter Mean 95%CI Point 
estimate 
Range Distribution Source/ Notes 
 PWID and HCV-related parameters  
HCV seroprevalence among PWID 
injecting < 3yrs (%) 
36.0 
 
22.9, 50.8   Normal 
 
Analysis of SNAP data.  Used to calibrate HCV transmission risk per year 
(among low-risk PWID not on MAT/SSP and 
injecting < 3yrs) (0.23; 95%CrI: 0.14-0.39) 
HCV seroprevalence among PWID 
injecting ≥ 3yrs (%) 
55.8 50.4, 61.3   Normal 
 
Analysis of SNAP data  
HCV seroprevalence among all 
PWID (%) 
53.3 48.2, 58.3   Normal Analysis of SNAP data  
HCV incidence per 100 pyrs 18.3 14.9, 22.4   Normal Analysis of SNAP data  
Population size of PWIDa    560–840 Uniform Analysis of SNAP data Estimated 700 PWID from analysis of SNAP data. 
Used to calibrate the rate that individuals initiate 
injecting per year to fit the sampled population size 
in 2009 and scale-up in injecting post-1990.   
Fold increase in number of 
individuals initiating injecting 
between 1990 and 2000.  
  8   Analysis of SNAP data.  Used to calibrate the increase in initiation rate of 
injecting between 1990 and 2000 
Overall duration of injecting (yrs)    5–25 Uniform  Young expanding population of injectors so 
uncertainty in duration of injecting - wide range 
assumed. 
Overall drug and non-drug mortality 
rate per year (%) 
1.0    Poisson Analysis of SNAP data  
Rate ratio for acquiring HCV if 
injecting < 3yrs compared to injecting 
≥3yrs 
2.2 1.4, 3.6   Log-normal Analysis of SNAP data  
 High-risk parameters  
Percentage of PWID that are high-
riskb in 2009 (%) 
14.5 13.0, 16.2   Normal Analysis of SNAP data   
Rate that PWID move from high to 
low-risk per year 
0.47 0.3, 0.6   Normal Analysis of SNAP data   
Rate ratio for acquiring HCV if high 
riskb compared to if low risk 
3.2 2.1, 5.0   Log-normal Analysis of SNAP data  
Proportion of PWID doing like-with-
like mixing by risk status (0 means 
random mixing and 1 means full like-
with-like mixing) 
   0–0.5 Uniform  No data so wide range assumed 
Proportion of PWID doing like-with-
like mixing by duration of injecting (0 
   0.4–0.8 
 
Uniform Analysis of SNAP data.  Fit to give 87.3% of PWID injecting ≥3 yrs inject 




means random mixing and 1 means 
full like-with-like mixing) 
 Intervention parameters  
Year MAT started in Perry County    1990–
2000 
Uniform   
Rate leave MAT/SSP per 100pyrsc    132–352 Uniform Analysis of SNAP data.  Gives 3.5 – 9 months on MAT/SSP. 
Coverage of MAT in 2009 (%) 4.7 3.8, 5.8   Normal Analysis of SNAP data.  Used to find the recruitment rate onto MAT 
Abbreviations – PWID: people who inject drugs; HCV: hepatitis C virus; SNAP: Social Networks Among Appalacian People; MAT: medication-assisted treatment; SSP: syringe service 
programs; 95%CI: 95% confidence interval; 95%CrI: 95% credible interval. aThe range for PWID population size is +/-20% of the estimated 700 PWID. bHigh-risk is defined as sharing works 




Table 3: Model parameters and calibration data with uncertainty bounds (usually 95% confidence intervals) for San Francisco.  
Parameter Mean 95%CI Point 
estimate 
Range Distribution Source Notes 
 PWID and HCV related parameters  
HCV antibody prevalence in 1999 
among 15-29yr olds (%) 
60.8  
 
53.9, 67.5   Normal 
 
35  
HCV antibody prevalence in 1999 





  Normal 35  
HCV antibody prevalence in 1999 
among 50+ yrs old (%) 
96.3 94.3, 98.7   Normal 35  Used to calibrate HCV transmission risk per year 
(among low-risk PWID not on MAT/SSP)  in those aged 
< 30 (0.39; 95%CrI: 0.26-0.58) and in those aged ≥ 30 
(0.14; 95%CrI: 0.08-0.28) 
HCV incidence per 100pyrs in 2001 
(< 30yrs) 
25.1 18.7, 32.9   Normal 32  Used to calibrate HCV transmission risk per year (given 
above). 
Proportion of PWID that start 











34 Little uncertainty so point estimate used.  
Calibrated to data on age of first injection from UHS34 
and size estimates 
Proportion of PWID that start 
injecting between 25-29 yrs old  




34 Little uncertainty so point estimate used.  
Calibrated to data on age of first injection from UHS34 
and size estimates 
Proportion of PWID that start 
injecting between 30-49 yrs old  
  0.1167  N/A 
 
34 Little uncertainty so point estimate used.  
Calibrated to data on age of first injection from UHS34 
and size estimates 
Number of years in 15-24 yrs age 
group 
  7.2 years  N/A 
 
UHS data34 15-24 year old PWID stay <10 years in first age group 
because on average enter at older age than 15  
Number of years in 25-29yrs age 
group 
  5.0 years  N/A UHS data34  
Number of years in 30-49yrs age 
group 
  20.0 
years 
 N/A UHS data34  













25    
Population size of PWID aged 30+ 
yrs old 
   10,988–
28,970 
Uniform 25    
Percentage of 30+yr old PWID that 
are 30-49 (%) 
   42.5–52.9 Uniform 25   Population size estimates25  and re-analysis of UHS data 
to get proportion of 30+ that are 30-49 years old. Used 
to calibrate the rate that individuals initiate injecting per 
year 
Overall drug and non-drug related 
mortality rate per year (%) 
0.91    Poisson 65  
Temporary cessation rate per year for 
15-29 yr olds 




Relapse rate to injecting per year for 
15-29yr olds 
0.56 0.4, 0.7   Uniform 36  
Relapse rate to injecting per year for 
30+yr olds 
0.30 0.2, 0.6   Uniform 36  
Years prior to 2017 when decrease in 
PWID initiation rate started  
   10–30 Uniform  Recruitment into injecting thought to have reduced in 
past but uncertain so large range 
Percentage of mixing being like-
with-like by age among those aged < 
30 (%) 
   54–62 N/A  Range used to determine proportion of PWID doing 
like-with-like mixing by age (0 means random mixing 
and 1 means full like-with-like mixing) (0.0004-0.46) 
 High risk parameters  
Percentage of PWID that are high 
riska pre-2002 (%) 
61.1 58.7, 63.5   Normal Analysis of UFO data  
Percentage of PWID that are high 
riska post-2002 (%) 
48.3 43.9,  52.6   Normal Analysis of UFO data  
Rate that PWID move from high to 
low risk per year 
1.6 1.3, 1.9   Normal Analysis of UFO data  
Rate ratio for acquiring HCV if high 
riska compared to if low-risk 
1.6 1.3, 2.1   Log-normal Analysis of UFO data  
Proportion of PWID doing like-with-
like mixing by risk status (0 means 
random mixing and 1 means full 
like-with-like mixing) 
   0–0.5 Uniform  No data so wide range assumed 
 Intervention parameters  
Year MAT started in San Francisco   2000  Point 
estimate 
 Coverage low before 2000 (UFO data) 
Rate leave MAT/SSP per year 1.0  0.7, 1.6   Normal 37  This gives 0.99 years (7.5 – 18 months on MAT/SSP) 
Coverage of MAT in 2004 (%) 2.6 1.8, 3.7   Normal Analysis of UFO data. Used to find the recruitment rate onto MAT. 
Coverage of MAT in 2015 (%) 12.2 10.3, 14.4   Normal Analysis of UFO data. Used to find the recruitment rate onto MAT. 
Coverage of SSP in 1997 among 15-




52.5, 84.9   Normal Analysis of NHBS data UHS data from 1997 has similar coverage to NHBS data 
from 2012, with NHBS data used to give coverage by 
age. Used to find the recruitment rate onto SSP for 
different age groups. 
Coverage of SSP in 1997 among 30-






  Normal Analysis of NHBS data UHS data from 1997 has similar coverage to NHBS data 
from 2012, with NHBS data used to give coverage by 
age. Used to find the recruitment rate onto SSP for 
different age groups. 
Coverage of SSP in 1997 among 50+ 
yrs old (%) 
 
88.1 83.7, 91.6   Normal  
 
Analysis of NHBS data UHS data from 1997 has similar coverage to NHBS data 
from 2012, with NHBS data used to give coverage by 
age. Used to find the recruitment rate onto SSP for 
different age groups. 
Abbreviations – PWID: people who inject drugs; HCV: hepatitis C virus; NHBS: National HIV Behavioural Surveillance; UHS: Urban Health Study; MAT: medication-assisted treatment; SSP: 




Table 4: Median and 95% credible intervals for the baseline projections, illustrative examples and treatment scale-up required for reaching 
WHO/ U.S. National Academies of Sciences, Engineering and Medicine elimination targets.  
 Perry County, Kentucky San Francisco 
 Median 95% CrI Median 95%CrI 
 Baseline projections  
Incidence in 2017 (/100pyrs) 21.3  10.2, 39.2 12.9  8.9, 18.4 
Prevalence in 2017 (%) 59.5  39.0, 75.0 75.5  66.6, 85.7 
 Treatment rates needed to decrease incidence by 90% by 2030 
Number of PWID needing treatment each 
year  
    
Without full HRa  58  30, 99 1574  940, 2319 
With full HRa 22  0, 52 1418  840, 2092 
Percentage of chronically infected PWID 
needing treatment in the first year  (%) 
    
Without full HRa 12.6 10.5, 16.5 9.3 7.9, 11.1 
With full HRa 4.7 0, 9.0 8.3  7.2, 9.9 
Abbreviations: 95%CrI: 95% credible interval; WHO: World Health Organisation; PWID: People who inject drugs; HR: Harm reduction; MAT: Medication assisted treatment; SSP: Syringe 
Service Provision. aFull HR is full harm reduction – 50% coverage of MAT and 84% coverage of SSP (scaled-up in Perry County only). 
